Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation

Circulation Journal

Volumn 72, Issue 11, 2008, Pages 1844-1851

  Yamamoto, Hiromi ^a   Takahashi, Kanako ^a   Watanabe, Haruyo ^a   Yoshikawa, Yuka ^a   Shirakawa, Ryutaro ^a   Higashi, Tomohito ^a   Kawato, Mitsunori ^a   Ikeda, Tomoyuki ^a   Tabuchi, Arata ^b   Morimoto, Takeshi ^a   Kita, Toru ^a   Horiuchi, Hisanori ^a  

^a KYOTO UNIVERSITY   (Japan)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antiplatelet; Cilostazol; Platelets; Prostaglandins; Signal transduction

Indexed keywords

ADENOSINE; ADENOSINE DIPHOSPHATE; CILOSTAZOL; COLLAGEN; CYCLIC AMP; PHOSPHODIESTERASE III INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN E1; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION; WESTERN BLOTTING;

ADULT; ALPROSTADIL; BLOOD PLATELETS; CELL ADHESION MOLECULES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TETRAZOLES;

EID: 55449087392     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0289     Document Type: Article

References (34)

1. Goto S. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; 6: 3-11.
2. Horiuchi H. Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems. Ann Med 2006; 38: 162-172.
3. Schleinitz MD, Olkin I, Heidenreich PA. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: A meta-analysis of randomized trials. Am Heart J 2004; 148: 990-997.
4. Sekiguchi M, Hoshizaki H, Adachi H, Ohshima S, Taniguchi K, Kurabayashi M. Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: A randomized comparison of ticlopidine and cilostazol. Circ J 2004; 68: 610-614.
5. Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients: Cilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008; 72: 35-39.
6. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832.
7. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-157.
8. Inoue T, Kobayashi M, Uetsuka Y, Uchiyama S. Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction. Circ J 2006; 70: 453-458.
9. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease. Int Angiol 2007; 26: 81-157.
10. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45(Suppl S): S5-S67.
11. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008; 47: 330-336.
12. Tanaka Y, Yamaki F, Koike K, Toro L. New insights into the intracellular mechanisms by which PGI2 analogues elicit vascular relaxation: Cyclic AMP-independent, Gs-protein mediated-activation of MaxiK channel. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 257-265.
13. Nakamura T, Uchiyama S, Yamazaki M, Iwata M. Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation. Thromb Res 2007; 119: 511-516.
14. Dutta-Roy AK, Kahn NN, Sinha AK. Prostaglandin E1: The endogenous physiological regulator of platelet mediated blood coagulation. Prostaglandins Leukot Essent Fatty Acids 1989; 35: 189-195.
15. Makita S, Nakamura M, Ohhira A, Itoh S, Hiramori K. Effects of prostaglandin E1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans. Cardiovasc Drugs Ther 1997; 11: 441-448.
16. Reinhard M, Jarchau T, Walter U. Actin-based motility: Stop and go with Ena/VASP proteins. Trends Biochem Sci 2001; 26: 243-249.
17. Massberg S, Gruner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler K, et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2004; 103: 136-142.
18. Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999; 18: 37-48.
19. Hauser W, Knobeloch KP, Eigenthaler M, Gambaryan S, Krenn V, Geiger J, et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci USA 1999; 96: 8120-8125.
20. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets: Definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
21. Yasunaga K, Mase K. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung 1985; 35: 1189-1192.
22. Tanemoto K, Kanaoka Y, Kuinose M. Assessment of antithrombotic agents using the platelet aggregation test. Curr Ther Res 2000; 61: 798-806.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
24. Smolenski A, Bachmann C, Reinhard K, Honig-Liedl P, Jarchau T, Hoschuetzky H, et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem 1998; 273: 20029-20035.
25. Tabuchi A, Taniguchi R, Takahashi K, Kondo H, Kawato M, Morimoto T, et al. Action of aspirin on whole blood-aggregation evaluated by the screen filtration pressure method. Circ J 2008; 72: 420-426.
26. Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999; 37(Suppl 2): 1-11.
27. Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, Anfossi G. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets: New insights into the antiaggregating effects of cAMP-elevating agents. Thromb Res 2004; 114: 265-273.
28. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
29. Lucas FV, Skrinska VA, Chisolm GM, Hesse BL. Stability of prostacyclin in human and rabbit whole blood and plasma. Thromb Res 1986; 43: 379-387.
30. Ignarro LJ. Nitric oxide: A novel signal transduction mechanism for transcellular communication. Hypertension 1990; 16: 477-483.
31. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
32. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-547.
33. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
34. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.